Krystal Biotech, Inc.KRYSNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
5.26%
↑ 154% above average
Average (36q)
-9.72%
Historical baseline
Range
High:228.16%
Low:-313.00%
Volatility
-5566.2%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 5.26% |
| Q2 2025 | 8.65% |
| Q1 2025 | -12.57% |
| Q4 2024 | 84.46% |
| Q3 2024 | 161.88% |
| Q2 2024 | 228.16% |
| Q1 2024 | -313.00% |
| Q4 2023 | 112.07% |
| Q3 2023 | 31.68% |
| Q2 2023 | 22.07% |
| Q1 2023 | -40.41% |
| Q4 2022 | -10.56% |
| Q3 2022 | -9.38% |
| Q2 2022 | -14.00% |
| Q1 2022 | -15.30% |
| Q4 2021 | -39.76% |
| Q3 2021 | 4.52% |
| Q2 2021 | -14.21% |
| Q1 2021 | -37.74% |
| Q4 2020 | -7.64% |
| Q3 2020 | -39.20% |
| Q2 2020 | -16.95% |
| Q1 2020 | 3.38% |
| Q4 2019 | -15.20% |
| Q3 2019 | 9.30% |
| Q2 2019 | -25.48% |
| Q1 2019 | -11.26% |
| Q4 2018 | -41.96% |
| Q3 2018 | -21.36% |
| Q2 2018 | -7.55% |
| Q1 2018 | -52.00% |
| Q4 2017 | 28.43% |
| Q3 2017 | -192.73% |
| Q2 2017 | -53.76% |
| Q1 2017 | 25.00% |
| Q4 2016 | -92.55% |
| Q3 2016 | 0.00% |